Optimizing Dyslipidemia Management for the Prevention of Cardiovascular Disease: a Focus on Risk Assessment and Therapeutic Options

Current Cardiology Reports
Adam N Berman, Ron Blankstein

Abstract

Primary prevention of incident atherosclerotic cardiovascular disease (ASCVD) as well as decreasing the risk of future events in those with established atherosclerosis is critical from a public health perspective. Management of dyslipidemias constitutes a key target in decreasing the risk of developing ASCVD events. While there have been great strides in the treatment of dyslipidemia over the last three decades, there are important recent developments and ongoing research that will expand the available therapeutic options and enable further cardiovascular risk reduction. PURPOSE OF REVIEW: The purpose of this paper is to review new developments relating to the primary prevention and management of ASCVD with a specific focus on optimizing the treatment of dyslipidemias. RECENT FINDINGS: In the realm of ASCVD risk prediction, mounting evidence over the last decade has demonstrated that coronary artery calcium testing is superior to any serum biomarker in the prediction of future ASCVD events and in discriminating future cardiovascular risk. As such, it has been incorporated into the most recent ACC/AHA primary prevention guideline to help guide management decisions in select patients. In terms of the management of dyslipidemias, ...Continue Reading

References

Jul 1, 1992·The Journal of Clinical Investigation·E BoerwinkleH H Hobbs
Aug 1, 1992·The American Journal of Clinical Nutrition·A M Dattilo, P M Kris-Etherton
Jun 6, 2003·European Heart Journal·R M ConroyUNKNOWN SCORE project group
Jan 1, 1963·Acta Pathologica Et Microbiologica Scandinavica·K BERG
Mar 17, 2004·Current Opinion in Lipidology·Marlys L Koschinsky, Santica M Marcovina
Aug 24, 2004·American Journal of Epidemiology·Melissa A AustinSteve E Humphries
Jul 20, 2007·JAMA : the Journal of the American Medical Association·Børge G NordestgaardAnne Tybjaerg-Hansen
Jul 20, 2007·JAMA : the Journal of the American Medical Association·Sandeep BansalPaul M Ridker
Sep 7, 2007·The New England Journal of Medicine·John D Brunzell
Nov 7, 2007·The New England Journal of Medicine·Philip J BarterUNKNOWN ILLUMINATE Investigators
Jan 24, 2008·Circulation·Ralph B D'AgostinoWilliam B Kannel
Jun 5, 2008·JAMA : the Journal of the American Medical Association·Ruth Frikke-SchmidtAnne Tybjaerg-Hansen
Jun 11, 2009·JAMA : the Journal of the American Medical Association·Pia R KamstrupBørge G Nordestgaard
Jul 23, 2009·JAMA : the Journal of the American Medical Association·UNKNOWN Emerging Risk Factors CollaborationJohn Danesh
Nov 12, 2009·JAMA : the Journal of the American Medical Association·UNKNOWN Emerging Risk Factors CollaborationJohn Danesh
Dec 25, 2009·The New England Journal of Medicine·Robert ClarkeUNKNOWN PROCARDIS Consortium
Jan 22, 2010·Circulation·Donald M Lloyd-JonesUNKNOWN American Heart Association Strategic Planning Task Force and Statistics Committee
Oct 23, 2010·European Heart Journal·Børge G NordestgaardUNKNOWN European Atherosclerosis Society Consensus Panel
Nov 17, 2011·The New England Journal of Medicine·William E BodenWilliam Weintraub
Nov 7, 2012·The New England Journal of Medicine·Gregory G SchwartzUNKNOWN dal-OUTCOMES Investigators
Feb 8, 2013·The New England Journal of Medicine·George ThanassoulisUNKNOWN CHARGE Extracoronary Calcium Working Group
May 24, 2013·The New England Journal of Medicine·Peter Libby
Oct 29, 2013·Journal of the American College of Cardiology·Pia R KamstrupBørge G Nordestgaard
Jan 30, 2014·European Heart Journal·Michael V HolmesJuan P Casas
Mar 13, 2014·Circulation. Cardiovascular Quality and Outcomes·Mark J PletcherPhilip Greenland
May 30, 2014·The American Journal of Clinical Nutrition·Miguel A Martínez-GonzálezUNKNOWN PREDIMED Group
Jul 12, 2014·The New England Journal of Medicine·Martin J LandrayJane Armitage
Aug 19, 2014·Lancet·Daniel J Rader, G Kees Hovingh
Aug 19, 2014·Lancet·Børge G Nordestgaard, Anette Varbo
Aug 30, 2014·Journal of the American College of Cardiology·Peter WilleitSotirios Tsimikas
Sep 6, 2014·Journal of the American College of Cardiology·Kunal N KarmaliDonald M Lloyd-Jones
Nov 19, 2014·The New England Journal of Medicine·Anand RohatgiPhilip W Shaul

❮ Previous
Next ❯

Citations

Jul 30, 2020·Journal of Clinical Laboratory Analysis·Xi SuLei Shang
Mar 18, 2020·Lipids in Health and Disease·Mahshad HedayatniaMajid Ghayour-Mobarhan
Aug 28, 2020·Current Rheumatology Reports·Marisa C Mizus, Eleni Tiniakou
May 25, 2021·Frontiers in Pharmacology·Sylvin Benjamin AtebaLiselotte Krenn

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.